In summary, our findings propose that common genetic variants in SLCO1B1 may serve as a novel pharmacogenetic biomarker for enalapril-induced cough in Chinese essential hypertensive patients because the SLCO1B1 521T > C polymorphism was associated with an increased risk of enalapril-induced cough. Here, SLCO1B1 is linked to hypertensive disorder.